Update on nonoxynol-9 as vaginal spermicide

European Journal of Contraception and Reproductive Health Care

Volumn 13, Issue 4, 2008, Pages 339-350

  Iyer, Vidya ^a   Poddar, S S ^a  

^a PRIN K M KUNDNANI COLLEGE OF PHARMACY   (India)

Author keywords

Cervical mucus; Contraceptive; Nonoxynol 9; Semen; Spermicide

Indexed keywords

ADVANTAGE 24; CELECOXIB; GYNOLL; INDOMETACIN; NONOXINOL 9; POVIDONE; PROPRANOLOL DERIVATIVE; TODAY; UNCLASSIFIED DRUG; VCF; CONTRACEPTIVE AGENT; NON PRESCRIPTION DRUG; NONOXINOL; SPERMICIDAL AGENT; SURFACTANT;

CHEMICAL INTERACTION; CHEMICAL STRUCTURE; CONCENTRATION RESPONSE; CONTRACEPTION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG MECHANISM; HUMAN; HYDROPHILICITY; LIPOPHILICITY; LOW DRUG DOSE; MICELLE; PHOTODEGRADATION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SPERM; TREATMENT FAILURE; UTERINE CERVIX MUCUS; VAGINA DISCHARGE; CHEMISTRY;

CONTRACEPTIVE AGENTS, FEMALE; HUMANS; NONOXYNOL; NONPRESCRIPTION DRUGS; SPERMATOCIDAL AGENTS; SURFACE-ACTIVE AGENTS;

EID: 64749099593     PISSN: 13625187     EISSN: 14730782     Source Type: Journal    
DOI: 10.1080/13625180802263515     Document Type: Review

References (82)

1. Helenius A, Simons K. Solubilization of membranes by detergents. Biochim Biophys Acta 1975; 415:29-79.
2. Chapvil M, Ulreich JB, O'Dea K, et al. Studies of nonoxynol-9. III. Effect of fibroblasts and spermatozoa. Fertil Steril 1980;33:521-5.
3. Yu K, Yie W. Spermicidal activity-structure relationship of nonoxynol oligomers: Physicochemical basis. Int J Pharm 1995;125:81-90.
4. Walter BA, Hawi AA, Zavos PM, Digensis GA. Solubilization and in vitro spermicidal assessment of nonoxynol-9 and selected fractions using rabbit spermatozoa. Pharm Res 1991;8:403-8.
5. Yu K, Bagdon RE, Yurkow EJ, Chien YW. Spermicidal activity of nonoxynol-9: quantitative assessment using flow cytometry. Drug Dev Indu Pharm 1995;21: 243-56.
6. Beer BE, Doncel GF, Krebs FC, et al. In vitro preclinical testing of nonoxynol-9 as potential anti-human immunodeficiency virus microbicide: a retrospective analysis of results from five laboratories. Antimicrob Agents Chemother 2006;50:713- 23.
7. Chantler E. Vaginal spermicides: some current concerns. Br J Fam Plann 1992;17:118-9.
8. Sander F, Cramer S. A practical method for testing the spermicidal action of chemical contraceptives. Hum Fertil 1941;6:134-7.
9. McConnell RF. Special requirements for testing spermicides. Acta Endocrinol 1974;75:373-86.
10. Van Damme L, Ramjee G, Alary M, et al. Effectiveness of COL-1492, nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: A randomized clinical trial. Lancet 2002;360: 971-7.
11. Over-the-counter vaginal contraceptive and spermicide drug products containing nonoxynol-9; required labeling. Final rule. Federal Register 2007;72: 71769-85.
12. Schill WB, Wolff HH. Ultrastructure of human spermatozoa in the presence of the spermicide nonoxynol-9 and a vaginal contraceptive containing nonoxynol-9. Andrologia 1981;13:42-9.
13. Wilborn WH, Hahn DW, McGuire JJ. Scanning electron microscopy of human spermatozoa after incubation with the spermicide nonoxynol-9. Fertil Steril 1983;39:717-9.
14. Zavos PM, Correa JR, Kaskar K, Zarmakoupis-Zavos PN. Time dependent pattern of activity of the spermicide nonoxynol-9 on sperm qualitative characteristics. Fertil Steril 2001;76(Suppl. 1):S263.
15. Becher P. Micelle formation in aqueous and nonaqueous solutions. In Schick M, ed. Nonionic surfactants. New York: Marcel Dekker, 1967:478- 515.
16. Candau P. Light scattering. In Zana R, ed. Surfactant solutions: New methods of investigation. New York: Marcel Dekker, 1987:158-78.
17. DeGiorgio V, Corti M. The micelle diffusion coefficient. J Col1 Interf Sci 1984;101:289-91.
18. Sunamoto J, Iwamoto K, Uesugi T, et al. Liposomal membranes: XVIII. Interaction of spermicidal agents with liposomal membranes. Chem Pharm Bull 1984;31:4230-5.
19. Furuse K, Ishizeki C, Iwahara S. Studies on the spermicidal activity of surfactants. 1. Correlation between spermicidal effect and physiochemical properties of p-menthanylphenyl polyoxyethylene (8.8) ether and related surfactants. J Pharm Dyn 1983;6:359-72.
20. Lee CH, Anderson M, Chien YW. Characterisation of in vitro spermicidal activity of chelating agent against human sperm. J Pharm Sci 1996;85:649-54.
21. Chantler E, Gwanmesia IL, Bruce JM. Diffusion of nonoxynol-9 into human semen in vitro. Contraception 1998;57:111-5.
22. Burruano BT, Schnaare RL, Malamud D. In vitro test to evaluate the interaction between synthetic cervical mucus and vaginal formulations. Contraception 2002;66: 137-40.
23. Umbreit JN, Strominger JL. Relation of detergent HLB number to solubilization and stabilization of D-alanine carboxypeptidase from Bacillus subtilis membrane. Proc Natl Acad Sci 1973;71:2997-3001.
24. Christian M. Cosmetic ingredient review: Final report on the safety assessment of nonoxynols -2, -4, -8, -9, -10, -12, -14, 15, 30, -40 and -50. J Am Coll Toxicol 1983;2:35.
25. Michel M, Dompmartin A, Moreau A, Leroy D. Contact sensitivity to nonoxynol used in antiseptic preparations. Photodermatol Photoimmunol Photomed 1994; 10:198-201.
26. Canudas N, Rivas C. Photodegradation of nonoxynol-9 in aqueous media. Studies of its in vitro phototoxicity. Internet J Sci Biol Chem 1997. http://www.netscijournal. com/97v4/97017/index.htm
27. Richardson BA, Martin HL, Stevens CE, et al. Use of nonoxynol-9 and changes in vaginal lactobacilli. J Infect Dis 1998;178:441-5.
28. Pascual LM, Daniele MB, Pa'jaro C, Barberis L. Lactobacillus species isolated from the vagina: Identification, hydrogen peroxide production and nonoxynol-9 resistance. Contraception 2006;73:78-81.
29. Halpern V, Rountree W, Raymond EG, Law M. The effects of spermicides containing nonoxynol-9 on cervical cytology. Contraception 2008;77:191-4.
30. Jain JK, Li A, Minoo P, et al. The effect of nonoxynol-9 on human endometrium. Contraception 2005;71:137-42.
31. Rosenstein IJ, Stafford MK, Kitchen VS, et al. Effect on normal vaginal flora of three intravaginal microbicidal agents potentially active against human immunodeficiency virus type 1. J Infect Dis 1998;177:1386-90.
32. Augenbraun MH, McCormack WM. Sexually transmitted diseases in HIV-infected persons. Infect Dis Clin North Am 1994;8:439-48.
33. Marais D, Cararra H, Kay P, et al. The impact of use of COL-1492, a nonoxynol-9 vaginal gel, on the presence of cervical human papillomavirus in female sex workers. Virus Res 2006;121:220-2.
34. Abrutyn D, McKenzie BE, Nadaskay N. Teratology study of intravaginally administered nonoxynol-9 containing contraceptive cream in rats. Fertil Steril 1982;37:113-7.
35. D'Cruz OJ, Shin MJ, Yiv SH, et al. Synthesis, characterization and preclinical formulation of a dualaction phenyl phosphate derivative of bromo-methoxy zidovudine (compound WHI- 07) with potent anti-HIV and spermicidal activities. Mol Hum Reprod 1999;5:421- 32.
36. Niruthisard S, Roddy RE, Chutivongse S. The effects of frequent nonoxynol-9 use on the vaginal and cervical mucosa. Sex Transm Dis 1991;18:176-9.
37. Rekart ML. The toxicity and local effects of the spermicide nonoxynol-9. J Acquir Immune Defic Syndr 1992;5:425-7.
38. Weir SS, Roddy RE, Zekeng L, Feldblum PJ. Nonoxynol-9 use, genital ulcers and HIV infection in a cohort of sex workers. Genitourin Med 1995;71:78- 81.
39. Roddy RE, Zekeng L, Ryan KA, et al. Effect of N-9 gel in urogenital gonorrhea and chlamydial infection: A randomized controlled trial. JAMA 2002;287:1117-22.
40. Richardson BA, Lavreys L, Martin HL, et al. Evaluation of a low dose nonoxynol-9 gel for the prevention of sexually transmitted diseases: a randomized clinical trial. Sex Transm Dis 2001;28:394-400.
41. Schreiber CA, Meyn LA, Creinin MD, et al. Effects of long-term use of nonoxynol-9 on vaginal flora. Obstet Gynecol 2006;107:136-43.
42. Van Damme L, Chandeying V, Ramjee G, et al. Safety of multiple daily applications of COL-1492, a nonoxynol-9 vaginal gel, among female sex workers. COL-1492 phase II study group. AIDS 2000;14:85-8.
43. Van Damme L, Niruthisard S, Atisook R. Safety evaluation of nonoxynol-9 gel in women at low risk of HIV infection. AIDS 1998;12:433-7.
44. Roddy RR, Cordero M, Cordero C, Fortney JA. A dosing study of nonoxynol-9 and genital irritation. Int J STD AIDS 1993;4:165-70.
45. Whang HS, Hunt MA, Wrench N, et al. Nonoxynol-9- a-cyclodextrin inclusion compound and its application for the controlled release of nonoxynol-9 spermicide. J Appl Polymer Sci 2007;106:4104-9.
46. Dunmire EN, Katz DF. Measurement and modulation of nonoxynol-9 diffusion and bioactivity against spermatozoa in human cervical mucus. Contraception 1997;55:115- 22.
47. Barditch-Crovob P, Witter F, Hamzeh F, et al. Quantitation of vaginally administered nonoxynol-9 in premenopausal women. Contraception 1997;55:261-3.
48. Dusitsin N, Gregoire AT, Johnson WD, Rakoff AE. Histidine in human vaginal fluid. Obstet Gynecol 1967;29: 125-9.
49. Huggins GR, Preti G. Vaginal odors and secretions. Clin Obstet Gynecol 1981;24:355-77.
50. Godley MJ. Quantitation of vaginal discharge in healthy volunteers. Br J Obstet Gynaecol 1985;92:739-42.
51. Wagner G, Levin RJ. Electrolytes in vaginal fluid during the menstrual cycle of coitally active and inactive women. J Reprod Fertil 1980;60:17-27.
52. Witter FR, Barditch-Crovob P, Rocco L, Trapnell CB. Duration of vaginal retention and potential duration of antiviral activity for five nonoxynol-9 containing intravaginal contraceptives. Int J Gynecol Obstet 1999; 65:165-70.
53. Doncel GF. Chemical vaginal contraceptives: preclinical evaluation. In Mauck CK, Cordero M, Gabelnick HL, et al., eds. Barrier contraceptives, current status and future prospects. New York: Wiley-Liss 1994:147-62.
54. Mauck CK, Allen S, Baker JM, et al. An evaluation of the amount of N-9 remaining in the vagina up to 4 hrs after insertion of a vaginal contraceptive film [VCF1] containing 70 mg N-9. Contraception 1997;56:103-10.
55. Moghissi KS. The function of the cervix in fertility. Fertil Steril 1972;23:295-306.
56. Roy S. Vaginal anatomy and physiology as they relate to sexual intercourse. In Mauck CK, Cordero M, Gabelnick HL, et al., eds. Barrier contraceptives, current status and future prospects. New York: Wiley-Liss 1994:77-89.
57. Katz DF, Couchman GM, Driscoll SL, et al. Posture influences vaginal gel distributions in women: In vivo studies. Fertil Steril 2001;76:S18.
58. Barnhart K, Pretorius ES, Stolpen A, Malamud D. Distribution of topical medication in the human vagina as imaged by MRI. Fertil Steril 2001;76:189-95.
59. Barnhart KT, Pretorius ES, Stolpen A, Malamud D. Distribution of spermicide containing nonoxynol-9 in the vaginal canal and the upper female reproductive tract. Hum Reprod 2001;16:1151-4.
60. Mauck CK, Katz D, Sandefer EP, et al. Vaginal distribution of Replens1 and K-Y1 jelly using three imaging techniques. Contraception 2008;77:195-204.
61. Trussell J, Kost K. Contraceptive failure in the United States: a critical review of the literature. Stud Fam Plann 1987;18:237-83.
62. Sharman D, Chantler E, Elstein M, et al. Comparison of the action of nonoxynol-9 and chlorhexidine on sperm. Fertil Steril 1986;45:259-65.
63. Hurd WW, Kelly MS, Ohl DA, et al. The effect of cocaine on sperm motility characteristics and bovine cervical mucus penetration. Fertil Steril 1992;57: 178-82.
64. Alexander NJ. Evaluation of male infertility with an in vitro cervical mucus penetration test. Fertil Steril 1981;36:201-8.
65. Zatuchni GI, Sobrero AJ, Speide JJ, Sciarra JJ, eds. Vaginal contraceptives: New developments. Hagerstown, MD: Harper and Row, 1979.
66. Dunmire EN, Katz F. Alteration of human sperm kinematics in cervical mucus due to nonoxynol-9. Contraception 1997;55:209-17.
67. Boyle CA, Khoury MJ, Katz DF, et al. The relation of computer-based measures of sperm morphology and motility to male infertility. Epidemiology 1992;3:239-46.
68. Barwicz J, Christian S, Gruda I. Effects of the aggregation state of amphotericin B on its toxicity to mice. Antimicrob Agents Chemother 1992;36:2310-5.
69. Yamashita K, Janout V, Bernard EM, et al. Micelle/ monomer control over the membrane-disrupting properties of an amphiphilic antibiotic. J Am Chem Soc 1995;117:249-53.
70. Tomecjek L, Reid G, Cuprerus PL, et al. Correlation between hydrophobicity and resistance to nonoxynol-9 and vancomycin for urogenital isolates of lactobacilli. FEMS Microbiol Lett 1992;73:101-4.
71. Stafford M, Ward H, Flanagan A, et al. Safety study of nonoxynol-9 as a vaginal microbicide: evidence of adverse effects. J Acquir Immune Defic Syndr Hum Retrovirol 1998;17:327-31.
72. Phillips D, Taylor C, Zacharopoulos V, Maguire R. Nonoxynol-9 causes rapid exfoliation of sheets of rectal epithelium. Contraception 2000;62:149-54.
73. Robinson B, Sullivan F, Borzelleca J, Schwartz S. PVP:A critical review of the kinetics and toxicology of polyvinylpyrrolidone. Chelsea, MI: Lewis Publishers, 1990.
74. Gagne N, Cormier H, Omar R, et al. Protective effect of a thermoreversible gel against the toxicity of nonoxynol- 9. Sex Transm Dis 1999;26:177-83.
75. Digenis GA, Rokem SS, Eckert D, Blecher L. Studies on the association of 14C-povidone-131I-iodine complex with red blood cells and bacterial membranes. In Digenis GA and Ansell J, eds. Proceedings of the International Symposium on Povidone. Lexington: University of Kentucky 1983:302-11.
76. Ben-David A, Gavendo S. The protective effect of polyvinylpyrrolidone and hydroxyethyl starch on noncryogenic injury to red blood cells. Cryobiology 1972;9:192-7.
77. Fowler PT, Doncel GF, Bummer PM, Digenis GA. Coprecipitation of nonoxynol-9 with polyvinylpyrrolidone to decrease vaginal irritation potential while spermicidal potency. AAPS Pharm Sci Tech 2003;4:1-8.
78. Zavos PM, Correa JR, Zarmakoupis-Zavos PN. Assessment of a tablet drug delivery system incorporating nonoxynol-9 coprecipitated with polyvinylpyrrolidone in preventing the onset of pregnancy in rabbits. Fertil Steril 1998;69:768-73.
79. Zavos PM, Correa JR, Nasek D, et al. Comparative spermicidal performance of iodinated and non-iodinated contraceptive formulations of nonoxynol-9 co-precipitated with polyvinylpyrrolidone. Contraception 1996;54: 39-41.
80. Lee CH, Bagdon R, Chien YW. Comparative in vitro spermicidal activity of chelating agents and synergistic effect with nonoxynol-9 on human sperm functionality. J Pharm Sci 1996;85:91-5.
81. White DR, Clarkson JS, Ratnasooriya WD, Aitken RJ. Complementary effects of propranolol and nonoxynol- 9 upon human sperm motility. Contraception 1995;52: 241-7.
82. Ingram MJ, Zeller E, Moss GP, Hall CE.Apotential antiimplantation and spermicidal strategy: Putative derivatives of nonoxynol-9 and anti-inflammatory agents and their spermicidal activity. Eur J Contracept Reprod Health Care 2006;11:258-61.